mRNA Combo Cuts High-Risk Melanoma Relapse

“Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA1). The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with […] The post mRNA Combo Cuts High-Risk Melanoma Relapse appeared first on Human Progress.